scholarly journals Low-dose temozolomide before dendritic-cell vaccination reduces (specifically) CD4+CD25++Foxp3+ regulatory T-cells in advanced melanoma patients

2013 ◽  
Vol 11 (1) ◽  
pp. 135 ◽  
Author(s):  
Laura Ridolfi ◽  
Massimiliano Petrini ◽  
Anna Granato ◽  
Giusy Gentilcore ◽  
Ester Simeone ◽  
...  
Keyword(s):  
T Cells ◽  
Dendritic Cell ◽  
Regulatory T Cells ◽  
Low Dose ◽  
Advanced Melanoma ◽  
Dendritic Cell Vaccination ◽  
Melanoma Patients

Changes in Peripheral Blood Level of Regulatory T cells in Patients with Malignant Melanoma During Treatment with Dendritic Cell Vaccination and Low-dose IL-2

2011 ◽  
Vol 73 (3) ◽  
pp. 222-233 ◽  
Author(s):  
J. Bjoern ◽  
M. K. Brimnes ◽  
M. H. Andersen ◽  
P. thor Straten ◽  
I. M. Svane
Keyword(s):  
T Cells ◽  
Dendritic Cell ◽  
Malignant Melanoma ◽  
Regulatory T Cells ◽  
Blood Level ◽  
Peripheral Blood ◽  
Low Dose ◽  
Dendritic Cell Vaccination

Dendritic cell (DC) vaccination with low dose temozolomide phase I/II trial in melanoma patients: Preliminary data on peripheral blood regulatory t-cells (Treg) and DC-TEM8 expression modulations.

2011 ◽  
Vol 29 (15_suppl) ◽  
pp. e13029-e13029
Author(s):  
M. Petrini ◽  
L. Ridolfi ◽  
L. Fiammenghi ◽  
M. Napolitano ◽  
A. M. Granato ◽  
...  
Keyword(s):  
T Cells ◽  
Dendritic Cell ◽  
Regulatory T Cells ◽  
Phase I ◽  
Preliminary Data ◽  
Peripheral Blood ◽  
Low Dose ◽  
Melanoma Patients

scholarly journals Skin-derived tumor specific T cells predict clinical outcome in dendritic cell vaccination studies in both stage III and IV melanoma patients

2010 ◽  
Vol 8 (S1) ◽  
Author(s):  
EHJG Aarntzen ◽  
W J Lesterhuis ◽  
M Van Rossum ◽  
G J Adema ◽  
C F Figdor ◽  
...  
Keyword(s):  
T Cells ◽  
Dendritic Cell ◽  
Clinical Outcome ◽  
Stage Iii ◽  
Dendritic Cell Vaccination ◽  
Melanoma Patients

Immunoregulatory T cells in the peripheral blood of melanoma patients treated with melanoma antigen-pulsed mature monocyte-derived dendritic cell vaccination

2009 ◽  
Vol 54 (1) ◽  
pp. 31-37 ◽  
Author(s):  
Noriaki Nakai ◽  
Norito Katoh ◽  
Tomoko Kitagawa ◽  
Eiichiro Ueda ◽  
Hideya Takenaka ◽  
...  
Keyword(s):  
T Cells ◽  
Dendritic Cell ◽  
Peripheral Blood ◽  
Dendritic Cell Vaccination ◽  
Melanoma Antigen ◽  
Melanoma Patients ◽  
Immunoregulatory T Cells

Clinical and Immunological Response Following hTERT/Survivin mRNA-Loaded Dendritic Cell Vaccination Combined With Ex-Vivo Expanded T Cell Transfer In Melanoma Patients

Blood ◽  
2013 ◽  
Vol 122 (21) ◽  
pp. 4487-4487
Author(s):  
Gunnar Kvalheim ◽  
Iris Bigalke ◽  
Siri Torhaug ◽  
Marianne Lundby ◽  
Camilla Mollat ◽  
...  
Keyword(s):  
Immune Response ◽  
T Cells ◽  
T Cell ◽  
Dendritic Cell ◽  
Ex Vivo ◽  
Dendritic Cell Vaccination ◽  
Cell Injection ◽  
Blood Samples ◽  
Melanoma Patients ◽  
T Cell Transfer

New immunotherapy strategies have recently been developed combining peptide or dendritic cell (DC) vaccination with infusion of vaccine-primed and ex vivo expanded T cells. The hypothesis is that adoptive transfer of ex vivo expanded tumor specific T cells can improve progression-free and overall survival by restoring anti-tumor immunity. In a phase I/II clinical trial on malignant melanomas stage IV patients received DC vaccination prior to transfer of ex vivo expanded T cells. Our strategy was to target hTERT and survivin since both is highly expressed in most cancers. The vaccine consisted of autologous DCs loaded with hTERT and survivin mRNA. Prior to each DC vaccination the patients received 5 days of Temozolomide treatment to reduce the number of regulatory T cells (Treg). Following 2 monthly DC vaccinations, blood samples were tested for immune response against hTERT and survivin overlapping peptides. Immune responders were offered injection of T cells. The Elutra fraction of T cells was depleted of Treg using Dynabeads CD25 prior to expansion with Dynabeads CD3/CD28 in a WAVE bioreactor. After 10 days the beads were removed and T cells were washed. 3x1010 expanded T cells were injected fresh and DC vaccination was continued. Prior to T cell infusion, the patients received non-myeloablative conditioning with Fludarabine and Cyclophosphamide Here we present the results from three patients receiving expanded T cells. Immune response against hTERT and survivin peptides were detected in blood samples from 7 to 11 weeks of DC vaccination. After 4-7 months of DC vaccination the T cells were expanded for 10 days prior to injection. DC vaccination was continued 1 day after T cell injection. Infused T cells expanded significantly in vivo and in two of the three patients currently tested both patients showed response against hTERT and survivin peptides. Blood samples taken monthly after T cell injection demonstrated immune response against the same peptides. In one of patients the number of Treg was high (> 4%) before and during vaccination and returned to low numbers (<1%) after T cell injection. Since these findings might explain the beneficial effect of the vaccination we are currently investigating if the number of Tregs in blood show the same profile in the two other patients. Progression free survival (PFS) in the three patients was 31,20 and 11 months respectively. Patients with the shortest PFS relapsed very shortly after the T-cell infusion in spite of an objective immunresponse following the last DC vaccine. Metastatic melanoma patients included in this study given DC vaccines without T-cells had a median PFS of 7 months (3-13). We therefore conclude that dendritic cell vaccination combined with ex-vivo expanded T cell transfer can be an efficient immunotherapy strategy in melanoma patients. Disclosures: No relevant conflicts of interest to declare.

Antigen targeting to endosomal pathway in dendritic cell vaccination activates regulatory T cells and attenuates tumor immunity

Blood ◽  
2006 ◽  
Vol 108 (4) ◽  
pp. 1298-1305 ◽  
Author(s):  
Mikael Maksimow ◽  
Mari Miiluniemi ◽  
Fumiko Marttila-Ichihara ◽  
Sirpa Jalkanen ◽  
Arno Hänninen
Keyword(s):  
T Cells ◽  
T Cell ◽  
Dendritic Cell ◽  
Regulatory T Cells ◽  
Antigen Processing ◽  
Cd4 T Cell ◽  
Cytotoxic T Cell ◽  
Dendritic Cell Vaccination ◽  
Lymphoma Cells ◽  
Self Antigen

Abstract Lymphoma cells are malignant cells of the T- or B-cell lineage that often express many surface markers inappropriately, yet are not recognized as abnormal by the immune system. We modeled this situation by inoculating ovalbumin-expressing E.G7-OVA lymphoma cells into mice that expressed ovalbumin as a self antigen in pancreatic islets, and investigated the efficacy of dendritic cell (DC) vaccination in these mice. Although vaccination with DC-expressing ovalbumin induced strong cytotoxic T-cell immunity, which led to clearance of E.G7-OVA lymphoma cells in naive C57BL/6 mice, DC vaccination was ineffective in mice expressing ovalbumin as a self antigen. Antigen modification to increase its processing via the endosomal processing pathway dramatically increased CD4 T-cell activation but paradoxically, impaired the protective effect of DC vaccination even in naive mice. Depletion of CD25+ T cells (regulatory T cells [Tregs]) prior to vaccination restored the efficacy of DC vaccination and allowed eradication of lymphoma also in mice expressing ovalbumin as a self antigen. We conclude that lymphoma cells may be eradicated using DC vaccination if activation of CD25+ Tregs is simultaneously inhibited, and that intentionally enhanced endosomal antigen processing in DC vaccines may shift the balance from CD4 T-cell help toward stimulation of Tregs.

Low-dose temozolomide modulation of peripheral blood regulatory T cells before dendritic cell-based vaccination in metastatic melanoma: Phase I/II study.

2010 ◽  
Vol 28 (15_suppl) ◽  
pp. TPS311-TPS311
Author(s):  
L. Ridolfi ◽  
L. Fiammenghi ◽  
M. Petrini ◽  
A. Granato ◽  
V. Ancarani ◽  
...  
Keyword(s):  
T Cells ◽  
Dendritic Cell ◽  
Regulatory T Cells ◽  
Phase I ◽  
Metastatic Melanoma ◽  
Peripheral Blood ◽  
Low Dose

Abstract 5518: Characterization of invariant natural killer T cells in patients with advanced melanoma treated with CTLA4 blockade and dendritic cell vaccination

2011 ◽  
Author(s):  
Javier -. Ibarrondo ◽  
Begoña -. Comin-Anduix ◽  
Yohan -. Lee ◽  
Thinle -. Chodon ◽  
Hooman -. Sazegar ◽  
...  
Keyword(s):  
T Cells ◽  
Dendritic Cell ◽  
Natural Killer ◽  
Natural Killer T Cells ◽  
Advanced Melanoma ◽  
Dendritic Cell Vaccination ◽  
Ctla4 Blockade ◽  
Killer T Cells ◽  
Invariant Natural Killer
Sign in / Sign up

Export Citation Format

Share Document